Molecular Templates Inc. (MTEM) is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immunotoxins for the treatment of cancer and other serious diseases. The company's proprietary drug platform, Engineered Toxin Bodies (ETBs), is based on genetically engineered fusion proteins that combine the targeting specificity of antibodies with the cell-killing activity of toxins.
Molecular Templates' lead product candidate is MT-3724, an ETB targeting the CD20 antigen for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing a number of other ETBs for the treatment of various types of cancer, including multiple myeloma, acute myeloid leukemia, and ovarian cancer.
In addition to its ETB platform, Molecular Templates is also developing biologic drugs based on its proprietary bi-functional antibody drug conjugate (BADCTM) technology. These drugs are designed to selectively target cancer cells and deliver a payload of drugs directly to the tumor.
The company is headquartered in Austin, Texas and was founded in 2003.
Molecular Templates Inc. (MTEM) is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of immunotoxins for the treatment of cancer and other serious diseases. The company's proprietary drug platform, Engineered Toxin Bodies (ETBs), is based on genetically engineered fusion proteins that combine the targeting specificity of antibodies with the cell-killing activity of toxins.